A Single-Centre, Single-Dose, Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the AbusePotential of AZD7325 in Healthy Recreational CNS Depressant Users.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 7325; Lorazepam
- Indications Anxiety disorders
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 24 Sep 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2009 New trial record